Skip to content
General News, Medical Health Aged Care

Access to physios and dietitians essential to address escalating arthritis crisis

Arthritis Australia 2 mins read
  • Arthritis Australia is calling for affordable, non-surgical care from physiotherapists, dietitians, and other allied health professionals to help stem the escalating arthritis crisis placing unprecedented strain on our communities, hospitals, and health budget. 

 

  • More than a third of Australians are living with arthritis and musculoskeletal conditions, including back pain. Together they are our most costly disease group with an annual burden of $15 billion.1 

 

  • Hip and knee replacements for osteoarthritis have reached a record high, averaging over 370 procedures per day and projected to more than double by 2030 to an unsustainable over 650 daily surgeries. 2,3,4 

 

  • Representatives of the arthritis community and leading experts will gather in Parliament House for the first time to address the escalating issues in arthritis and musculoskeletal care. 

 

  • Research shows education and support for exercise, weight loss, and pain management through allied health professionals can reduce costly hip and knee replacements by a third - saving $1.01 billion annually.5 

Available for interviews: 

  • Jonathan Smithers – CEO, Arthritis Australia 

Details: 

Location: Private Dining Room, Parliament House Canberra  

Date & Time: Thursday 22nd August 2024, 9.30am – 1.00pm 

 

Issued by Cube on behalf of Arthritis Australia. For more information, please contact: Anne-Marie Sparrow on 0417 421 560 or Kayla Behayi on 0403 425 572 

 

References 

  1. Australian Institute of Health and Welfare (2023) Health system spending on disease and injury in Australia, 2020-21, AIHW, Australian Government, accessed 25 January 2024. 

  1. Ackerman I et. al., (2019). The projected burden of primary total knee and hip replacement for osteoarthritis in Australia to the year 2030. Accessed 13 August 2024 

  1. Australian Orthopaedic Association National Joint Replacement Registry, Procedures Reported (hip and knee). Accessed at https://aoanjrr.sahmri.com/procedures-reported. 

  1. Ackerman, I.N., Bohensky, M.A., Zomer, E. et al. The projected burden of primary total knee and hip replacement for osteoarthritis in Australia to the year 2030. BMC Musculoskelet Disord20, 90 (2019). https://doi.org/10.1186/s12891-019-2411-9  

  1. Ackerman IN, Skou ST, Roos EM, Barton CJ, Kemp JL, Crossley KM, Liew D, Ademi Z. Implementing a national first-line management program for moderate-severe knee osteoarthritis in Australia: A budget impact analysis focusing on knee replacement avoidance. Osteoarthr Cartil Open. 2020 May 6;2(3):100070. doi: 10.1016/j.ocarto.2020.100070. PMID: 36474677; PMCID: PMC9718332. 

 


About us:

About Arthritis Australia

Arthritis Australia is the peak national body for arthritis, advocating on behalf of over 4 million Australians living with arthritis, and working with many other arthritis organisations to deliver information and support to people living with more than 100 types of arthritis and musculoskeletal conditions. We are a leading non-government funder of arthritis research in Australia and advocate for policies, programs and funding initiatives that will improve the health and wellbeing of people living with arthritis. For more information visit: arthritisaustralia.com.au

More from this category

  • Medical Health Aged Care
  • 18/03/2026
  • 18:41
Samsung Bioepis Co., Ltd.

Samsung Bioepis Enters into Partnership Agreement with Sandoz for Up to Five Next-Generation Biosimilar Candidates

The agreement covers up to five assets, including SB36, a biosimilar candidate referencing Entyvio (vedolizumab), for collaboration of development and commercialization in global markets excluding China, Hong Kong, Taiwan, Macau, and Republic of KoreaSamsung Bioepis continues to pave the way for access to life-changing medicines by advancing a biosimilar pipeline across immunology and oncology   INCHEON, Korea--BUSINESS WIRE-- Samsung Bioepis Co., Ltd. announced today that the company has entered into a global license, development and commercialization agreement (DCA) with Sandoz for up to five biosimilar candidates under development by Samsung Bioepis, including SB36, a biosimilar candidate referencing Entyvio1 (vedolizumab). The…

  • Contains:
  • Medical Health Aged Care
  • 18/03/2026
  • 16:49
Palliative Care Australia

Better end-of-life care for older Australians must be the next step in aged care reform

Palliative Care Australia this week brought leaders from aged care, palliative care, health, advocacy, research and policy together in Melbourne for its inauguralPalliative Care…

  • Contains:
  • General News, Transport Automotive
  • 18/03/2026
  • 16:15
NIEIR (National Institute of Industry and Economic Research)

EV Adoption in Australia Still Dominated by High-Income Areas, Study Finds

Key Facts: EV ownership in Australia is concentrated in wealthy metropolitan areas, with average EV-owning households in Local Government Areas earning around $150,000 Metropolitan…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.